- Jefferies analyst raised the Thermo Fisher Scientific price target to $630.00, suggesting a 10.02% upside.
- The company reported strong Q2 financial performance, with adjusted EPS of $6.03 and quarterly sales of nearly $12.00 billion, surpassing analyst expectations.
- Thermo Fisher Scientific demonstrated broad-based growth across all business segments and announced a strategic partnership, boosting investor confidence.
Thermo Fisher Scientific (NYSE: TMO) is a global leader that provides scientific instrumentation, reagents, and software services. This healthcare technology and biotech sector giant recently saw its outlook improve. On July 23, 2026, Jefferies analyst Tycho Peterson raised the price target for Thermo Fisher Scientific to $630.00. This new target suggests a potential 10.02% upside from the stock’s price of $572.60 at the time of the announcement, reflecting positive investment analysis.
This analyst optimism is supported by Thermo Fisher Scientific’s strong second-quarter performance. The company reported adjusted earnings per share (EPS) of $6.03, a key measure of profitability per share. This figure surpassed the street’s expectation of $5.71 and marked a 13% increase from the previous year, as highlighted by Zacks, indicating robust financial performance.
The company’s quarterly sales also showed significant strength, climbing 10% year-over-year to nearly $12.00 billion. This result exceeded the analyst consensus estimate of $11.70 billion. This performance was driven by a 5% organic revenue growth, which indicates an increase in sales from the company’s core operations, showcasing strong market growth.
Growth was evident across all of Thermo Fisher Scientific’s business segments. Life Sciences Solutions sales increased by 12.6% to $2.80 billion. Additionally, Analytical Instruments sales grew by 6.9% to $1.80 billion, and Laboratory Products and Biopharma Services sales rose by 11.6% to $6.70 billion, showing broad-based strength in the biotech sector.
Further supporting this positive market outlook, Thermo Fisher Scientific announced a partnership with Arcturus for the development of a cystic fibrosis treatment. Following the strong earnings report, the company’s stock rose 4.4% in pre-market trading, as highlighted by Zacks, reflecting strong investor confidence and positive stock market news.
